Karyopharm Reports Second Quarter 2023 Financial Results and

– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023...

Related Keywords

Israel , China , United States , South Korea , Boston , Massachusetts , Tsadal , Kyongsang Bukto , United Kingdom , American , Richard Paulson , Trademark Office , Drug Administration , European Hematology Association , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , Selective Inhibitor Of Nuclear Export , Menarini Group , Karyopharm Selective Inhibitor Of Nuclear Export , Company Ongoing Pivotal Phase , Linkedin , American Society Of Clinical Oncology , Information Department , Foundation Medicine Inc , Karyopharm Therapeutics Inc , Optimization Of Corporate Organization , Nasdaq , Karyforward Patient Assistance Program , Achieved Second Quarter , Net Product Revenue , Maintains Full Year , Revenue Guidance , Product Revenue Guidance , Workforce Reduction Enhancing Financial Strength , Further Reduces Full Year , Expense Guidance , Cash Runway , Initiated Pivotal Phase , Received Fast Track Designation , Providing Further Rationale , Ongoing Pivotal Phase , Endometrial Cancer , Conference Call Scheduled , Chief Executive Officer , American Society , Clinical Oncology , Fast Track Designation , Microsatellite Stable , Foundation Medicine , United States Patent , Corporate Organization , Financial Position , Revenue Interest Financing Agreement , Healthcare Royalty Partners , Chief Scientific , Chief Executive , Call Information , Karyopharm Therapeutics , Selective Inhibitor , Nuclear Export , Medical Information , Fetal Toxicity , Private Securities Litigation Reform Act , Quarterly Report ,